Equillium, Inc.

We are a biotechnology company focused on developing new treatments for severe autoimmune and inflammatory disorders. Our main goal is to advance EQ504, a new aryl hydrocarbon receptor (AhR) modulator, through clinical development. EQ504 is in the preclinical stage and has shown therapeutic benefits in various models by increasing anti-inflammatory cells and cytokines, reducing pro-inflammatory cells and cytokines, and improving intestinal tissue barrier function and repair. We initially plan to develop EQ504 for ulcerative colitis (UC) and other gastrointestinal (GI) diseases, with potential future expansion into inflammatory lung diseases. We also have EQ302, a preclinical-stage, first-in-class, selective, bi-specific inhibitor of IL-15 and IL-21, designed for oral delivery. Inhibiting IL-15 and IL-21 is considered a potential treatment for certain GI conditions, including celiac disease. We have conducted preclinical development for EQ302, including in vivo pharmacology studies and formulation development, and are evaluating its further advancement, including manufacturing and toxicology studies to support a potential investigational new drug (IND) filing and a first-in-human clinical study. Our pipeline of therapeutic candidates aims to address unmet medical needs in gastroenterology, dermatology, and pulmonology. Our strategy includes completing the preclinical and clinical development of EQ504 and evaluating the further advancement of EQ302. We intend to start a Phase 1 proof-of-mechanism study for EQ504 in mid-2026, with data expected approximately six months later.